<DOC>
	<DOCNO>NCT02426333</DOCNO>
	<brief_summary>The purpose study explore whether early abiraterone exposure relate treatment response patient metastatic castration resistant prostate cancer . Furthermore explore relation biomarkers treatment response drug exposure .</brief_summary>
	<brief_title>Optimizing Abiraterone Therapy</brief_title>
	<detailed_description />
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Patients metastatic castration resistant prostate cancer asymptomatic mildly symptomatic failure androgen deprivation therapy chemotherapy yet clinically indicated Age â‰¥18 year Feasible collect blood sample Life expectancy &gt; 6 month Measurable disease Able willing give write informed consent prior screen enrollment anticancer therapy potent CYP3A4 inducer herbal medicine could interfere abiraterone exposure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>